NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System
News provided by
Share this article
LOS ANGELES, Jan. 22, 2021 /PRNewswire/
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders, announces that the Centers for Medicare & Medicaid Services ( CMS ) is establishing two new Level II Healthcare Common Procedure Coding System ( HCPCS ) codes for the
Monarch eTNS System®, effective April 1, 2021, as part of the final coding decisions of its
. The new codes are K1016 (Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve) and K1017 (Monthly supplies for use of device coded at K1016). Securing these codes is an important milestone in enabling payer coverage and payment decisions.
Share this article
Share this article
LOS ANGELES, Jan. 12, 2021 /PRNewswire/ Monarch Biosciences, Inc. (MonarchBio), a California-based life sciences company, announced today that it has recently received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for the following U.S. patent applications:
No. 16/298,758 entitled Three-Dimensional Thin-Film Nitinol Devices (U.S. Patent 10,864,096)
No. 16/010,341 entitled Intrasaccular Thin-film Flow Diverters and Related Methods
No. 15/605,754 entitled Thin-Film Cuff for Endothelialization of Endovascular Grafts
No. 16/048,136 entitled Thin-Film Micromesh and Related Methods
Haynes and Boone LLP represented MonarchBio in the successful prosecution of these patent applications and other related applications.
The claims of the patent applications cover the manufacturing of three-dimensional thin-film nitinol (TFN) constructs and include TFN-based intrasaccular flow diverters, cuffs for endovascular